# Regeneron will tie Medicaid drug pricing to benchmarks in other developed countries.

*biotech · news · 2026-04-24 · Benzinga*

## Key points

- Regeneron will tie Medicaid drug pricing to international benchmarks under a new White House agreement.
- Praluent will be available for direct purchase at a most-favored-nation price on TrumpRx.gov.
- Regeneron will provide its FDA-approved hearing loss gene therapy, Otarmeni, free in the U.S.
- The agreement grants Regeneron three years of tariff relief in exchange for domestic investment commitments.

**Companies:** Regeneron
**Countries:** United States

[Read the full story on Benzinga](https://www.benzinga.com/news/fda/26/04/52038230/regeneron-strikes-deal-with-trump-administration-to-cut-drug-prices)

---

Canonical: https://newsio.io/n/476218c6-8381-41e6-b72a-b02aea13413b/regeneron-will-tie-medicaid-drug-pricing-to-benchmarks-in-other-developed-countr
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works